Abstract Title:

Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis.

Abstract Source:

Appl Physiol Nutr Metab. 2020 Jan 14. Epub 2020 Jan 14. PMID: 31935118

Abstract Author(s):

José Antonio Valle Flores, Juan Enrique Fariño Cortéz, Gabriel Alexei Mayner Tresol, Juan Perozo Romero, Miquel Blasco Carlos, Teresa Nestares

Article Affiliation:

José Antonio Valle Flores


Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death due to cardiovascular complications by 2-3 times compared to the general population. This research concerns a prospective, randomized, double-blind study in patients with CKD undergoing hemodialysis. The participants were assigned to one of two groups: the study group (group A; 46 patients) received four capsules (2.4 g) of omega-3 fatty acids daily during the 12-week intervention, while patients in the control group (group B; 47 patients) received four capsules of paraffin oil. The patients' general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin-6, interleukin-10 and tumour necrosis factor alpha) were evaluated. No differences were found between the general characteristics of the patients (P<0.05), and no differences were shown in the nutritional indicators and markers of kidney disease (P<0.05). Patients in group A showed significant decreases in levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio after 12 weeks of supplementation (P<0.05). Patients in group B did not show any significant changes in concentrations of inflammatory markers during the intervention (P<0.05). In conclusion, oral supplementation with omega-3 fatty acids produces a significant decrease in the concentrations of inflammation markers in patients with chronic kidney disease on hemodialysis. Novelty bullets:●Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers. ●This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.

Print Options

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.